Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs

Toxicology and Applied Pharmacology

Volumn 272, Issue 2, 2013, Pages 365-372

  Turowska, Agnieszka ^a   Librizzi, Damiano ^b   Baumgartl, Nadja ^c   Kuhlmann, Jens ^a   Dicke, Tanja ^a   Merkel, Olivia ^d   Homburg, Ursula ^a   Höffken, Helmut ^b   Renz, Harald ^c   Garn, Holger ^c  

^a Sterna Biologicals GmbH and Co KG   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

DNAzyme; GATA 3; Hgd40; Pharmacokinetics; SPECT

Indexed keywords

ANTIASTHMATIC AGENT; MESSENGER RNA; RADIOISOTOPE; RIBOZYME; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR GATA 3 SPECIFIC DNAZYME HGD40; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG UPTAKE; EXPERIMENTAL DOG; FEMALE; IN VIVO STUDY; ISOTOPE LABELING; LUNG PARENCHYMA; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; URINARY EXCRETION;

DNAZYME; GATA-3; HGD40; PHARMACOKINETICS; SPECT;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DNA, CATALYTIC; DOGS; FEMALE; GATA3 TRANSCRIPTION FACTOR; LUNG; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; RATS; RATS, WISTAR; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84883775024     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.06.020     Document Type: Article

References (22)

1. Bitko V., Musiyenko A., Shulyayeva O., Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005, 11(1):50-55.
2. Brown-Augsburger P., Yue X.M., Lockridge J.a., McSwiggen J.a., Kamboj D., Hillgren K.M. Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices. J. Pharm. Biomed. Anal. 2004, 34(1):129-139.
3. Darcan-Nicolaisen Y., Meinicke H., Fels G., Hegend O., Haberland A., Kühl A., Loddenkemper C., et al. Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. J. Immunol. 2009, 182(12):7501-7508.
4. Dass C.R., Saravolac E.G., Li Y., Lun Quan S. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 2002, 299:289-299.
5. Dicke T., Pali-Schöll I., Kaufmann A., Bauer S., Renz H., Garn H. Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes. Nucleic Acid Ther. 2012, 22(2):117-126.
6. Fuhst R., Runge F., Buschmann J., Ernst H., Praechter C., Hansen T., von Erichsen J., et al. Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure. Pulm. Pharmacol. Ther. 2012, 6-14.
7. Geary R.S., Leeds J.M., Fitchett J.O.N., Burckin T., Truong L., Spainhour C., Creek M., et al. Pharmacokinetics and metabolism of a phosphorothioate oligonucleotide antisense inhibitor of c-raf-1 kinase expression. Pharmacology 1997, 25(11):1272-1281.
8. Geary R.S., Yu R.Z., Watanabe T., Henry S.P., Hardee G.E., Chappell A., Matson J., et al. Pharmacokinetics of a tumor necrosis factor-phosphorothioate 2-0-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Pharmacology 2003, 31(11):1419-1428.
9. Grimpe B. Deoxyribozymes: new therapeutics to treat central nervous system disorders. Front. Mol. Neurosci. 2011, 4:1-5.
10. Jason T.L.H., Koropatnick J., Berg R.W. Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 2004, 201(1):66-83.
11. Lee C.-C., Huang H.-Y., Chiang B.-L. Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol. Ther. 2007, 16(1):60-65.
12. Lee S.-Y., Huh M.S., Lee S., Lee S.J., Chung H., Park J.H., Oh Y.-K., et al. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J. Control. Release 2010, 141(3):339-346.
13. Merkel O.M., Beyerle A., Librizzi D., Pfestroff A., Behr T.M., Sproat B., Barth P.J., et al. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm. 2009, 6(4):1246-1260.
14. Merkel O.M., Librizzi D., Pfestroff A., Schurrat T., Buyens K., Sanders N.N., De Smedt S.C., et al. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by fluorescence fluctuation spectroscopy and single photon emission com. J. Control. Release 2009, 138(2):148-159.
15. Merkel O.M., Zheng M., Mintzer M.a., Pavan G.M., Librizzi D., Maly M., Höffken H., et al. Molecular modeling and in vivo imaging can identify successful flexible triazine dendrimer-based siRNA delivery systems. J. Control. Release 2011, 153(1):23-33.
16. Rivory L., Tucker C., King A., Lai A., Goodchild A., Witherington C., Gozar M.M., et al. The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity. Oligonucleotides 2006, 16(4):297-312.
17. Saleem A., Matthews J.C., Ranson M., Callies S., André V., Lahn M., Dickinson C., et al. Molecular imaging and pharmacokinetic analysis of carbon-11 labeled antisense oligonucleotide LY2181308 in cancer patients. Theranostics 2011, 1:290-301.
18. Santoro S.W., Joyce G.F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(9):4262-4266.
19. Sel S., Wegmann M., Dicke T., Sel S., Henke W., Yildirim A.O., Renz H., et al. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J. Allergy Clin. Immunol. 2008, 121(4):910-916.
20. Verma N., Tripathi S.K., Chaudhury I., Das H.R., Das R.H. iNOS-targeted 10-23 DNAzyme reduces LPS-induced systemic inflammation and mortality in mice. Shock 2010, 33(5):493-499.
21. Wegmann M., Fehrenbach H., Fehrenbach a, Held T., Schramm C., Garn H., Renz H. Involvement of distal airways in a chronic model of experimental. Clin. Exp. Allergy 2005, 35(10):1263-1271.
22. Yu R.Z., Kim T.-won, Hong A., Watanabe T.A., Gaus H.J., Geary R.S. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 2007, 35(3):460-468.